Peter Dunleavy - Search Results

Year	Number of Results
2008	1
2009	1
2012	1
2017	1
2018	2
2019	1
2020	2
2021	0

1

Perioperative intravenous contrast administration and the incidence of acute kidney injury after major gastrointestinal surgery: prospective, multicentre cohort study.

STARSurg Collaborative. STARSurg Collaborative. Br J Surg. 2020 Jul;107(8):1023-1032. doi: 10.1002/bjs.11453. Epub 2020 Feb 5. Br J Surg. 2020. PMID: 32026470

2

Prognostic model to predict postoperative acute kidney injury in patients undergoing major gastrointestinal surgery based on a national prospective observational cohort study.

STARSurg Collaborative. STARSurg Collaborative. BJS Open. 2018 Jul 27;2(6):400-410. doi: 10.1002/bjs5.86. eCollection 2018 Dec. BJS Open. 2018. PMID: 30513129 Free PMC article.

3

Correction to: Challenges of one-year longitudinal follow-up of a prospective, observational cohort study using an anonymised database: recommendations for trainee research collaboratives.

STARSurg Collaborative. STARSurg Collaborative. BMC Med Res Methodol. 2020 Feb 7;20(1):27. doi: 10.1186/s12874-020-0909-3. BMC Med Res Methodol. 2020. PMID: 32033542 Free PMC article.

4

Challenges of one-year longitudinal follow-up of a prospective, observational cohort study using an anonymised database: recommendations for trainee research collaboratives.

STARSurg Collaborative, Nepogodiev D. STARSurg Collaborative, et al. BMC Med Res Methodol. 2019 Dec 12;19(1):237. doi: 10.1186/s12874-019-0857-y. BMC Med Res Methodol. 2019. PMID: 31830925 Free PMC article.

5

Association between peri-operative angiotensin-converting enzyme inhibitors and angiotensin-2 receptor blockers and acute kidney injury in major elective non-cardiac surgery: a multicentre, prospective cohort study.

STARSurg Collaborative. STARSurg Collaborative. Anaesthesia. 2018 Oct;73(10):1214-1222. doi: 10.1111/anae.14349. Epub 2018 Jul 9. Anaesthesia. 2018. PMID: 29984818 Free article.

6

Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.

Stone J, Martin NK, Hickman M, Hutchinson SJ, Aspinall E, Taylor A, Munro A, Dunleavy K, Peters E, Bramley P, Hayes PC, Goldberg DJ, Vickerman P. Stone J, et al. Addiction. 2017 Jul;112(7):1302-1314. doi: 10.1111/add.13783. Epub 2017 Mar 3. Addiction. 2017. PMID: 28257600 Free PMC article.

7

Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.

May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaut R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, D'Arminio Monforte A, Vehreschild JJ, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC). May MT, et al. Int J Epidemiol. 2012 Dec;41(6):1807-20. doi: 10.1093/ije/dys164. Epub 2012 Nov 12. Int J Epidemiol. 2012. PMID: 23148105 Free PMC article.

8

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.

Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M. Antiretroviral Therapy Cohort Collaboration (ART-CC), et al. Clin Infect Dis. 2009 Apr 15;48(8):1138-51. doi: 10.1086/597468. Clin Infect Dis. 2009. PMID: 19275498 Free PMC article.

The greatest mortality hazard ratio was associated with non-Hodgkin's lymphoma (hazard ratio, 17.59; 95% confidence interval, 13.84-22.35) and progressive multifocal leukoencephalopathy (hazard ratio, 10.0; 95% confidence interval, 6.70-14.92). Three groups of ADEs were id …

The greatest mortality hazard ratio was associated with non-Hodgkin's lymphoma (hazard ratio, 17.59; 95% confidence interval, 13.84-2 …

9

Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial.

Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, Nicholson AG, O'Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MK; MS01 Trial Management Group. Muers MF, et al. Lancet. 2008 May 17;371(9625):1685-94. doi: 10.1016/S0140-6736(08)60727-8. Lancet. 2008. PMID: 18486741 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results